Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Immunol. 2013 Dec;34(12):592-601. doi: 10.1016/j.it.2013.07.002. Epub 2013 Aug 5.

B cell receptor signaling in chronic lymphocytic leukemia.

Author information

1
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: jaburger@mdanderson.org.

Abstract

B cell receptor (BCR) signaling plays an important pathogenic role in chronic lymphocytic leukemia (CLL) and B cell lymphomas, based on structural restrictions of the BCR, and BCR-dependent survival and growth of the malignant B cells. In CLL and lymphoma subtypes, ligand-independent ('tonic') and ligand-dependent BCR signaling have been characterized, which can involve mutations of BCR pathway components or be triggered by (auto)antigens present in the tissue microenvironment. In CLL, based on high response rates and durable remissions in early-stage clinical trials, there is rapid clinical development of inhibitors targeting BCR-associated kinases [Bruton's tyrosine kinase (BTK), phosphoinositide 3-kinase (PI3K)δ], which will change treatment paradigms in CLL and other B cell malignancies. Here, we discuss the evolution of this field, from BCR-related prognostic markers, to mechanisms of BCR activation, and targeting of BCR-associated kinases, the emerging Achilles' heel in CLL pathogenesis.

KEYWORDS:

B cell receptor; Bruton's tyrosine kinase; chronic lymphocytic leukemia; microenvironment; phosphoinositide 3-kinase δ; spleen tyrosine kinase

PMID:
23928062
PMCID:
PMC3898793
DOI:
10.1016/j.it.2013.07.002
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center